DRD2 and diffuse midline glioma: In nonfunctioning pituitary adenomas, cabergoline (NCT02288962, Phase III, active) activates D2R to inhibit proliferation, whereas in recurrent diffuse midline gliomas, ONC206 (NCT04732065, Phase I, recruiting) inhibits D2R to induce apoptosis.